Article thumbnail

Contraception in HIV-positive female adolescents

By Nadia T Kancheva Landolt, Sudrak Lakhonphon and Jintanat Ananworanich


Sexual behavior of HIV-positive youths, whether infected perinatally, through risky behavior or other ways, is not substantially different from that of HIV-uninfected peers. Because of highly active antiretroviral therapy, increasing number of children, infected perinatally, are surviving into adolescence and are becoming sexually active and need reproductive health services. The objective of this article is to review the methods of contraception appropriate for HIV-positive adolescents with a special focus on hormonal contraceptives. Delaying the start of sexual life and the use of two methods thereafter, one of which is the male condom and the other a highly effective contraceptive method such as hormonal contraception or an intrauterine device, is currently the most effective option for those who desire simultaneous protection from both pregnancy and sexually transmitted diseases. Health care providers should be aware of the possible pharmacokinetic interactions between hormonal contraception and antiretrovirals. There is an urgent need for more information regarding metabolic outcomes of hormonal contraceptives, especially the effect of injectable progestins on bone metabolism, in HIV-positive adolescent girls

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). A: Hormonal contraception in HIV-Positive Women. AIDS Reader
  2. (2009). A: Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy
  3. (2007). ACTG A5093 Protocol Team: Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther
  4. (1996). Adolescent condom use, the health belief model, and the prevention of sexually transmitted disease.
  5. (2001). Adolescent Medicine HIV/AIDS Research Network: Incident pregnancy rates in HIV infected and HIV uninfected at-risk adolescents.
  6. Agenerase (amprenavir), package insert.
  7. (2005). Alnabawy AK, Kaptein MC: Comparison of ethinylestradiol pharmacokineticss in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception
  8. (2008). Association: UK Guidelines for the management of sexual and reproductive health of people living with HIV infection.
  9. (2008). Bahamondes L: Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril
  10. (2009). Chaithongwongwatthana S: Awareness of Emergency Contraception in Adolescent Mothers.
  11. (2008). Cocohoba JM: Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.
  12. (2008). Coerced and forced sterilization of HIV-positive women
  13. Contraceptive Injection, medroxyprogesterone acetate injectable suspension, USP.
  14. (2008). Coutsoudis A: Messages about dual contraception in areas of high HIV prevalence are not heeded.
  15. Crixivan (indinavir), package insert.
  16. (2010). D’Angelo L: Sexual transmission risk behavior of adolescents With HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr
  17. (1998). DM: Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers. Conf Retrovir Oppor Infect
  18. (2006). Dual protection: more needed than practised or understood. Reprod Health Matters
  19. (2008). Effect of efavirenz on the pharmacokinetics of ethinyl estradiol and norgestimate in healthy female subjects.
  20. (2011). EK: Use of the Copper T380A Intrauterine Device by Adolescent Mothers: Continuation and Method Failure. J Pediatr Adolesc Gynecol
  21. (2004). Eligibility Criteria for Contraceptive Use.
  22. (2000). Estrogen protects against vaginal transmission of simian immunodeficiency virus.
  23. (2003). Ethier K: Perinatal Guidelines Evaluation Project. Dual contraceptive method use for pregnancy and disease prevention among HIV-infected and HIV-uninfected women: the importance of an event-level focus for promoting safer sexual behaviors. Sex Transm Dis
  24. (2007). GC: Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS
  25. (2008). GJ: Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/ zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
  26. (1998). Granneman GR: Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
  27. (2005). Greenblatt RM: Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy.
  28. (2004). Haefeli WE: Oral contraception does not alter single dose saquinavir pharmacokinetics in women.
  29. (2006). HB: Regret following female sterilization at a young age: a systematic review. Contraception
  30. HIV-Infected Youth. [ fvd6vkink4vw7dwdxzrfz6nareomrt6ah4ufcqkzftpbi3bwbsl6p7p3m bqaw6uqi5lp7vjxc/YL29e.pdf].
  31. (2008). Hoetelmans RM: Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther
  32. (2009). Hoetelmansa RM: Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception
  33. (2010). Hogue CJ: Condoms for dual protection: patterns of use with highly effective contraceptive methods. Public Health Rep
  34. (2008). Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther
  35. (2002). How oestrogen or progesterone might change a woman’s susceptibility to HIV-1 infection.
  36. (2009). HV: Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception. Contraception
  37. (2008). Intrauterine devices and adolescents. Curr Opin Obstet Gynecol
  38. (2007). JS: A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus.
  39. (2009). JS: HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS
  40. (2010). LK: Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections. Contraception
  41. (1992). MG: Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception
  42. (2009). Morakote N: Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study.
  43. (2009). MTCTPlus Initiative: Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. AIDS
  44. (2010). Non-contraceptive benefits of hormonal contraceptives. Minerva Ginecol
  45. (2003). O’Mara E: Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects. Conf Retrovir Oppor Infect
  46. (2006). Oleske JM: Sexual behaviors and procreational intentions of adolescents and young adults with perinatally acquired human immunodeficiency virus infection: experience of an urban tertiary center.
  47. (2004). PA: Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS
  48. (2009). PC: Hormonal contraception and metabolic outcomes in women with or at risk for HIV infection. J Acquir Immune Defic Syndr
  49. (2007). Phanuphak P: Health Risk Behaviors among HIV-Infected Youth in Bangkok, Thailand.
  50. (2002). Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-Infected women. J Acquir Immune Defic Syndr
  51. (2001). Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott Williams and Wilkins;
  52. (2001). Progestogen-only injectable hormonal contraceptive use should be considered in analysis of studies addressing the loss of bone mineral density in HIV-positive women.
  53. (2001). Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG
  54. RH: Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai,
  55. (2008). Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception
  56. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009, 23(suppl 1):S55-S67.
  57. (2010). SE: Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr
  58. (2008). Semple SJ: Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez,
  59. (2003). Sexual health and development of adolescents and youth in the Americas: program and policy implications.
  60. (2010). Sexual life and contraception in people living with HIV. Asian Biomedicine
  61. (2010). Stanczyk FZ: Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception
  62. (2004). Stephens E: Contraception choice for HIV positive women. Sex Transm Infect
  63. (2010). Succi RM: Pregnancy in HIV vertically infected adolescents and young women: a new generation of HIVexposed infants.
  64. (2007). The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis
  65. (2010). TT: Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis
  66. (2009). UNAIDS: Report on the global AIDS epidemic.
  67. Viracept (nelfinavir) package insert.